Traders assign a 92.5% probability that no new COVID-19 variant of concern will be designated before 2027 because current SARS-CoV-2 evolution remains confined to Omicron descendants without meeting WHO criteria for elevated transmissibility, severity, or immune escape. Dominant lineages such as XFG continue to drive most cases, prompting routine 2026-2027 vaccine updates rather than signaling a major shift. More divergent strains under monitoring, including BA.3.2 and PQ.16.1.1, show limited prevalence below 1% in clinical sequencing and low global risk assessments despite some immune-evasion mutations. Declining surveillance volumes add uncertainty, yet no rapid replacement or concerning growth advantage has appeared in the past several months, leaving little time for a qualifying event before year-end.